ITIKA Tablet 90mg (Ticagrelor)

Adult dosage

Patients taking this medicine should also receive a maintenance dose of aspirin (75 ∼ 150mg), unless specifically contraindicated. This medicine should not be used concomitantly with other ADP receptor inhibitors (ticlopidine, clopidogrel, prasugrel). Acute coronary syndrome: Administer an initial dose of 180mg, followed by 90mg twice daily. Treatment for 12 months is recommended unless discontinuation of this medicine is clinically necessary. Patients with a history of myocardial infarction (occurring at least 1 year previously) who are at high risk of atherothrombotic cardiovascular events: Administer 60mg twice daily. Patients who took 90mg of this medicine or another ADP receptor inhibitor (ticlopidine, clopidogrel, prasugrel) during the first year after myocardial infarction may continue treatment with 60mg of this medicine. Treatment with this medicine may also be initiated in patients within 2 years after myocardial infarction or within 1 year after discontinuing a previous ADP receptor inhibitor (ticlopidine, clopidogrel, prasugrel). The safety and efficacy of this medicine were evaluated at 3 years of follow-up. This medicine is administered orally and may be taken with or without food. For patients who have difficulty swallowing tablets, crush this medicine into a fine powder, disperse it in half a glass of water, and drink it immediately. Rinse the glass used for administration with half a glass of water and drink the rinse. This mixture may also be administered through a nasogastric tube (CH8 or larger); it is important to flush the nasogastric tube with water after administration. When switching from another antiplatelet agent to this medicine, start this medicine 24 hours after the last dose of the previous medicine. If a dose is missed, take only 1 tablet (the next scheduled dose) at the next scheduled dosing time. No dose adjustment is necessary in patients with renal impairment. Since information on the use of this medicine in patients receiving renal dialysis is unavailable, its use is not recommended in these patients. No dose adjustment is necessary in patients with mild hepatic impairment. This medicine has not been studied in patients with severe hepatic impairment, and experience with its use in patients with moderate hepatic impairment is limited.

Children's dosage

The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age.

This drug prevents blood from clotting to avoid thrombus formation. However, it can cause severe bleeding, so it should not be used in patients with bleeding or a history of intracranial hemorrhage. If surgery is planned, this medication should be discontinued at least 7 days prior, and if bleeding symptoms occur, consult a doctor immediately. Additionally, patients who are allergic to this drug or have severely impaired liver function should also not be administered this medication. Patients at high risk of bleeding or who are taking other drugs that may cause bleeding should use this medication cautiously. In particular, patients who have recently experienced trauma or surgery, those with blood coagulation disorders, or those who have had gastrointestinal bleeding require care. During treatment with this drug, symptoms of bleeding or side effects such as shortness of breath may frequently occur, and if any unusual symptoms appear, medical staff should be informed immediately. Patients with asthma or chronic obstructive pulmonary disease should be particularly careful as shortness of breath may worsen. Elderly patients, those with impaired kidney function, or with a history of hyperuricemia or gout should regularly check kidney function and uric acid levels while taking this medication. Furthermore, this drug may interact with other medications, so inform your doctor or pharmacist of any other medications you are taking. Pregnant or breastfeeding women are advised to avoid using this drug, and women of childbearing age should take appropriate contraceptive measures to avoid pregnancy. The safety and efficacy of this drug in pediatric patients or those under 18 years of age have not been established and it is not recommended. In case of overdose, the risk of bleeding increases, therefore appropriate medical treatment should be sought immediately and it is critical not to discontinue this medication arbitrarily. Keep this medication out of the reach of children and store it in its original container to maintain its quality. Dizziness or confusion may occur while taking this medication, so care is required when driving or operating machinery.

• Hemorrhage
• dyspnea
• tumor hemorrhage
• blood disease hemorrhage
• hyperuricemia
• gout
• confusion
• dizziness
• syncope
• headache

This drug may be sensitive to air or moisture, so it must be stored in a sealed container. The recommended storage temperature is room temperature between 1 degree and 30 degrees Celsius. This will help maintain the effectiveness of the drug for a longer period.

Appearance

Yellow, round, biconvex, film-coated tablet

Package unit

60 tablets (10 tablets/PTP*6)